Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus
- Conditions
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01465113
- Locations
- 🇺🇸
University Hospitals Ahuja Medical Center, Beachwood, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 133
- Registration Number
- NCT01462318
- Locations
- 🇵🇱
Research Site, Krakow, Poland
Proton Pump Inhibitors and Dysbiosis in Cirrhosis
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2018-03-19
- Target Recruit Count
- 60
- Registration Number
- NCT01458990
- Locations
- 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01415128
Use of Maytenus Ilicifolia in the Treatment of Dyspepsia
- Conditions
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Casa Espirita Terra de Ismael
- Target Recruit Count
- 4
- Registration Number
- NCT01408849
- Locations
- 🇧🇷
Hospital das Clinicas FMRP-USP, Ribeirao Preto, SP, Brazil
A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01392755
Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis
- Conditions
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2013-03-06
- Target Recruit Count
- 36
- Registration Number
- NCT01389401
- Locations
- 🇧🇷
Otolaryngology Department of Santa Casa School of Medicine and Hospitals of São Paulo Brazil, São Paulo, Brazil
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 195
- Registration Number
- NCT01338077
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan
Oral OKT3 for the Treatment of Active Ulcerative Colitis
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01287195
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
BAY73-4506 Probe Substrate Study
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 41
- Registration Number
- NCT01287598
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.